Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 12/20 | 0.55 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750941 | 0.93 | TOP2A (0.47) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL11750031 | 0.86 | TOP2A (0.54) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL7489756 | 0.83 | TOP2A (0.54) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL29372928 | 0.83 | TOP2A (0.54) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL11745243 | 0.83 | TOP2A (0.37) | TOP2ATOP2BKMT2ALMNATP53 | |
| SCHEMBL11747964 | 0.81 | TOP2A (0.58) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL11749326 | 0.80 | TOP2A (0.49) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL11747960 | 0.80 | TOP2A (0.56) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL7495129 | 0.79 | TOP2A (0.50) | TOP2ATOP2BRAD52HTTPOLB | |
| SCHEMBL10477218 | 0.74 | TOP2A (0.58) | TOP2ATOP2BRAD52HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094952-A | Pyrazolopyridine-based DNA-dependent protein kinase inhibitors and compositions and their use in gene editing | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094961-A | DNA-dependent protein kinase inhibitors and compositions based on 5, 6-core silacycle and their use in gene editing | — | 2026-05-26 | — | — | CN | claimed |
| US-20260123175-A1 | COMPOUNDS HAVING FLUORENE STRUCTURES | MERCK PATENT GMBH (DE) | 2026-04-30 | — | — | US | claimed |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2025-12-23 | — | — | US | claimed |
| US-20250368595-A1 | NOVEL MOLECULES | Xeniopro GmbH (DE) | 2025-12-04 | — | — | US | claimed |
| US-20250368666-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES INC (US) | 2025-12-04 | — | — | US | claimed |
| US-12435067-B2 | Truncated itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-10-07 | — | — | US | claimed |
| WO-2025201532-A1 | NOVEL PEGYLATION COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (SHANGHAI) LIMITED., CO. (CN) | 2025-10-02 | — | — | WO | claimed |
| US-20250299853-A1 | HOT DEFORMED MAGNET | TDK CORPORATION (JP) | 2025-09-25 | — | — | US | claimed |
| EP-3983388-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | Nodthera Limited (GB) | 2022-04-20 | — | — | EP | claimed |
| US-20220110955-A1 | DEUTERATED DERIVATIVES OF PSILOCYBIN AND USES THEREOF | Lennham Pharmaceuticals, Inc. | 2022-04-14 | — | — | US | claimed |
| EP-3980404-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| WO-2022068921-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-04-07 | — | — | WO | claimed |
| CN-114261970-A | Transition metal oxide molecular sieve and preparation method and application thereof | 宁波大学 | 2022-04-01 | — | — | CN | claimed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3967683-A1 | SUBSTITUTED FLUORINE-CONTAINING IMIDAZOLE SALT COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Xiamen Vivohealths Technology Co., Ltd. (CN) | 2022-03-16 | — | — | EP | claimed |
| CN-110441453-B | Method for separating and detecting phosphamidon isomers | 国家烟草质量监督检验中心 | 2022-03-15 | — | — | CN | claimed |
| WO-2022042657-A1 | COMPOUNDS AND METHODS OF USE | Ferro Therapeutics, Inc. (US) | 2022-03-03 | — | — | WO | claimed |
| CN-114100603-A | In for degrading perfluorooctanoic acid2O3Photocatalyst and preparation method thereof | 清华大学深圳国际研究生院 | 2022-03-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110955-A1 | DEUTERATED DERIVATIVES OF PSILOCYBIN AND USES THEREOF | DRD2, DRD3, CNR2 | TOP2A 2682/4885TOP2B 1301/4885RAD52 3166/4885 |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, PTK2B | TOP2A 2579/4885TOP2B 2887/4885RAD52 3949/4885 |
| US-20250368595-A1 | NOVEL MOLECULES | MUSK, IKZF3, TYR | TOP2A 3103/4885TOP2B 3095/4885RAD52 832/4885 |
| US-20260123175-A1 | COMPOUNDS HAVING FLUORENE STRUCTURES | NR0B1, NR0B2, NR2E1 | TOP2A 2630/4885TOP2B 1203/4885RAD52 1779/4885 |
| US-20250368666-A1 | INDAZOLE COMPOUNDS | FGFR1, FGFR3, FGFR2 | TOP2A 1453/4885TOP2B 1130/4885RAD52 3865/4885 |
| US-12435067-B2 | Truncated itraconazole analogues and methods of use thereof | GLI1, SHH, SMO | TOP2A 3796/4885TOP2B 3235/4885RAD52 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.